Uoshima Nobuhiko, Kamitsuji Yuri, Maruya Etsuko, Saji Hiroh
Department of Internal Medicine, Matsushita Memorial Hospital, Moriguchi, Osaka, Japan.
Int J Hematol. 2003 Jul;78(1):69-72. doi: 10.1007/BF02983243.
A 31-year-old woman with advanced acute myeloid leukemia underwent non-T-cell-depleted (TCD) peripheral blood stem cell transplantation (PBSCT) with a reduced-intensity conditioning regimen. The donor was an HLA haploidentical 3-loci-mismatched complementary sibling who had not inherited maternal HLA antigens. Long-term fetomaternal microchimerism was detected by nested polymerase chain reaction with specific primer typing. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus with minidose methotrexate. Durable engraftment was achieved without severe acute GVHD, and complete remission was obtained. Thus non-TCD HLA haploidentical reduced-intensity PBSCT based on fetomaternal immunological tolerance appears to be feasible. Our results have important implications in the selection of alternative donors and conditioning regimens for allogeneic hematopoietic stem cell transplantation.
一名31岁的晚期急性髓系白血病女性患者接受了非T细胞去除(TCD)的外周血干细胞移植(PBSCT),采用了减低强度预处理方案。供者为一名HLA单倍型相合、3个位点不相合的互补同胞,其未遗传母体HLA抗原。通过巢式聚合酶链反应和特异性引物分型检测到长期的母胎微嵌合体。移植物抗宿主病(GVHD)预防方案包括他克莫司和小剂量甲氨蝶呤。实现了持久植入,无严重急性GVHD,并获得完全缓解。因此,基于母胎免疫耐受的非TCD HLA单倍型相合减低强度PBSCT似乎是可行的。我们的结果对异基因造血干细胞移植替代供者和预处理方案的选择具有重要意义。